Patents Examined by Bao Q Li
  • Pathogen-specific cargo delivery and diagnostic platform based on mesoporous silica nanoparticles
    Patent number: 11045555
    Abstract: In various embodiments nanoparticle drug delivery vehicles are provided that specifically deliver a cargo to a target pathogenic organism. In certain embodiments the drug delivery vehicle comprises a mesoporous silica nanoparticle comprising a plurality of pores and an outer surface through which the pores are disposed; a cargo disposed in the pores; one or more antigens attached to the surface of the nanoparticle; an antibody that specifically binds the antigens and are bound to the antigens, wherein the antibody inhibits diffusion of the cargo out of the pores and permit release of the cargo when the drug delivery vehicle is in the presence of the antigen or a pathogen displaying the antigen.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: June 29, 2021
    Assignee: The Regents of the University of California
    Inventors: Jeffrey I. Zink, Bastian Ruehle, Marcus A. Horwitz, Daniel L. Clemens, Bai-Yu Lee Clemens
  • Rapid and prolonged immunologic therapeutic
    Patent number: 11040099
    Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).
    Type: Grant
    Filed: July 11, 2020
    Date of Patent: June 22, 2021
    Assignee: Altimmune, Inc.
    Inventor: De-Chu C Tang
  • Rapid and prolonged immunogic therapeutic
    Patent number: 11040100
    Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).
    Type: Grant
    Filed: July 12, 2020
    Date of Patent: June 22, 2021
    Assignee: Altimmune Inc.
    Inventor: De-Chu C Tang
  • Multivalent vaccines for rabies virus and coronaviruses
    Patent number: 11041170
    Abstract: The present disclosure provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a coronavirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a coronavirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present disclosure provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one coronavirus immunogenic glycoprotein fragment, as well as pharmaceutical compositions comprising the vaccine vectors.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: June 22, 2021
    Assignees: Thomas Jefferson University, The United States of America, as represented by the Secretary, Department of Health & Human Service, University of Maryland
    Inventors: Reed F. Johnson, Matthias Schnell, Lisa E. Hensley, Christoph Wirblich, Christopher M. Coleman, Matthew B. Frieman
  • Half-life optimized linker composition
    Patent number: 11028132
    Abstract: Coronavirus disease 2019 (COVID-19 or COVID-2) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Common symptoms include fever, cough, and shortness of breath. The virus is mainly spread during close contact and via respiratory droplets produced when people cough or sneeze. Respiratory droplets may be produced during breathing but the virus is not generally airborne. A half-life optimized fusion composition linked by a Half-Life Optimizing (H-Lo) linker comprising of a receptor binding domain (RBD), a half-life extending domain (LED), wherein the LED is any one of a monoclonal antibody, single domain antibody, nanobody, antibody fragment, or combination thereof and the H-Lo linker with an X+7 amino acid length fusing the RBD C-terminus with the LED N-terminus (RBD-LED fusion) is discussed in the invention.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: June 8, 2021
    Inventor: Yitzhak Rosen
  • Compositions and methods for detecting human papillomavirus nucleic acid
    Patent number: 10988816
    Abstract: Disclosed are nucleic acid oligomers, including amplification oligomers, capture probes, and detection probes, for detection of a human papillomavirus (HPV) nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding reaction mixtures and kits.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: April 27, 2021
    Assignee: GEN-PROBE INCORPORATED
    Inventor: Astrid R. W. Schroder
  • Preparation of influenza virus vaccine antigens
    Patent number: 10946088
    Abstract: A number of improvements for preparing vaccine antigens from disintegrated influenza viruses are disclosed. A splitting step can be followed by detergent exchange. Splitting can take place in the presence of a buffer with a higher ionic strength and/or in the presence of phosphate buffer.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: March 16, 2021
    Assignee: Seqirus UK Limited
    Inventors: Christoph Haussmann, Frank Hauschild, Bjorn Jobst
  • Engineered virus
    Patent number: 10947513
    Abstract: The present invention relates to oncolytic virus comprising: (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: March 16, 2021
    Assignee: Replimune Limited
    Inventor: Robert Coffin
  • Method and kit for quantifying vaccine
    Patent number: 10942181
    Abstract: The present disclosure provides a method for quantifying a vaccine. The method includes the steps of: 1) providing a plurality of standard mixtures, each of the standard mixtures having a standard antigen and an aluminum based adjuvant; 2) mixing a stabilizing solution with the vaccine and each of the standard mixtures; 3) determining dosages of the standard antigens in the standard mixtures to establish a standard curve; and 4) determining a dosage of a target antigen in the vaccine according to the standard curve.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: March 9, 2021
    Assignee: Adimmune Corporation
    Inventors: Juine-Ruey Chen, Chia-Ying Wu, Yung-Tsung Chen
  • Universal vaccine for viral diseases
    Patent number: 10940196
    Abstract: The present invention relates to a pharmaceutical combination for inducing one or more immune responses and/or for enhancing effectiveness of vaccination in the host, which is capable of inducing cross-protection against multiples strains and/or serotypes of a virus. In one embodiment, the pharmaceutical combination is able to generate protection in food producing animals, such as cattle, sheep, goats, swine and other cloven-hoofed animals with fewer vaccination campaigns.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: March 9, 2021
    Assignee: BIOGENESIS BAGÓ HONG-KONG LIMITED
    Inventors: Rodolfo César Bellinzoni, Emmanuel Gérard Etienne Régulier, Ana Romo
  • Adjuvant compositions
    Patent number: 10940202
    Abstract: This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: March 9, 2021
    Assignee: Zoetis Services LLC
    Inventors: Paul Joseph Dominowski, Ramasamy Mannar Mannan, Richard Lee Krebs, James Richard Thompson, Tedd Alan Childers, Mary Kathryn Olsen, Robert John Yancey, Jr., Risini Dhammika Weeratna, Shucheng Zhang, Cedo Martin Bagi
  • Methods and compositions for inducing protective immunity against a marburg virus infection
    Patent number: 10925956
    Abstract: Compositions, vaccines and methods using a combination of adenovirus vectors and MVA vectors for inducing protective immunity against a Marburg virus infection are described.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: February 23, 2021
    Assignees: Janssen Vaccines & Prevention B.V., Bavarian Nordic A/S
    Inventors: Benoit Christophe Stephan Callendret, Ramon Roozendaal, Jutta Sytske Hartkoorn-Pasma, Ariane Volkmann, Robin Steigerwald, Ulrike Dirmeier
  • Vaccines with CD40 ligand as an adjuvant
    Patent number: 10925961
    Abstract: Disclosed herein is a vaccine comprising an antigen and CD40L. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: February 23, 2021
    Assignees: The Trustees of the University of Pennsylvania, INOVIO PHARMACEUTICALS. INC.
    Inventors: David Weiner, Matthew Morrow, Megan Wise
  • Zika virus vaccines
    Patent number: 10913776
    Abstract: Disclosed is an immunogen comprising a fusion protein, wherein the fusion protein comprises a Zika virus (ZIKV) envelope protein, optionally a signal peptide, and a multimerization domain. The signal peptide is a premembrane (prM) signal peptide, an IgG signal peptide, or a human secretory signal peptide hidden Markov model, and the multimerization domain is an immunoglobulin Fc domain, a T4 fibritin foldon trimerization domain, or a human collagen XV trimerization domain. Nucleic acids, vectors, and microneedle arrays including these compositions are disclosed. Methods of producing an immune response to ZIKV are also disclosed.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: February 9, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Andrea A. Gambotto, Eun Kim, Geza Erdos, Louis D. Falo, Jr.
  • Chimeric hepatitis D virus antigen and hepatitis B virus pre S1 genes for use alone or in vaccines containing hepatitis B virus genes
    Patent number: 10905760
    Abstract: Disclosed herein are chimeric genes, compositions of chimeric genes, and compositions of polypeptides that are useful for the generation, enhancement, or improvement of an immune response to a target antigen. Some embodiments of the compositions include chimeric genes encoding hepatitis D antigen (HDAg) protein in combination with one or more self-cleavage 2A polypeptides and a preS 1 polypeptide. In certain embodiments the self-cleavage polypeptide is P2A.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: February 2, 2021
    Assignee: Svenska Vaccinfabriken Produktion AB
    Inventors: Matti Sällberg, Lars Frelin
  • Recombinant B11 bacteriophages and uses thereof
    Patent number: 10900025
    Abstract: The present disclosure provides compositions including recombinant B11 bacteriophages, methods for making the same, and uses thereof. The recombinant B11 bacteriophages disclosed herein are useful for the identification and/or antibiotic susceptibility profiling of specific bacterial strains/species present in a sample.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: January 26, 2021
    Assignee: The Charles Stark Draper Laboratory, Inc.
    Inventors: Connor McBrine, Georgiana Kourepenos, Parker Dow, Jason Holder
  • Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist
    Patent number: 10894831
    Abstract: Methods are provided for targeting cells for depletion, including without limitation tumor cells, in a regimen comprising contacting the targeted cells with a combination of agents that modulate immunoregulatory signaling. Immunoregulatory modulating agents include (i) an agent that blockades CD47 activity; and (ii) an agent that agonizes an immune costimulatory molecule, e.g. CD137. The regimen may further comprise an agent that specifically binds to the target cell, e.g. an antibody or biologically active fragment or derivative thereof. The level of depletion of the targeted cell is enhanced relative to a regimen in which a single immunoregulatory modulating agent is used; and the effect may be synergistic relative to a regimen in which a single immunoregulatory modulating agent is used.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: January 19, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Peter Schnorr, Akanksha Chhabra, Judith A. Shizuru, Irving L. Weissman, Kipp Andrew Weiskopf
  • Human immunodeficiency virus neutralizing antibodies and methods of use thereof
    Patent number: 10889633
    Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: January 12, 2021
    Assignees: The Rockefeller University, California Institute of Technoloqy
    Inventors: Johannes Scheid, Michel Nussenzweig, Pamela J. Bjorkman, Ron Diskin
  • Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance
    Patent number: 10889649
    Abstract: Methods and compositions are provided for inducing phagocytosis of a target cell, treating an individual having cancer, treating an individual having an intracellular pathogen infection (e.g., a chronic infection), and/or reducing the number of inflicted cells (e.g., cancer cells, cells infected with an intracellular pathogen, etc.) in an individual. Methods and compositions are also provided for predicting whether an individual is resistant (or susceptible) to treatment with an anti-CD47/SIRPA agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent. In some cases, the subject methods and compositions include an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent (e.g., co-administration of an anti-MHC Class I/LILRB1 agent and an anti-CD47/SIRPA agent). Kits are also provided for practicing the methods of the disclosure.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: January 12, 2021
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Roy Louis Maute, Kipp Andrew Weiskopf, Aaron Michael Ring, Irving L. Weissman
  • Antibody, composite, detection device and method using same
    Patent number: 10883991
    Abstract: The present invention is an antibody including an amino acid sequence, wherein the amino acid sequence includes, in an N- to C-direction, the following structural domains: N-FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4-C wherein FR denotes a framework region amino acid sequence and CDR denotes a complementary determining region amino acid sequence; the CDR1 includes an amino acid sequence represented by SEQ ID NO: 1; the CDR2 includes an amino acid sequence represented by SEQ ID NO: 2; and the CDR3 includes an amino acid sequence represented by SEQ ID NO: 3. The antibody is capable of binding to an intranuclear protein of an influenza virus.
    Type: Grant
    Filed: June 5, 2019
    Date of Patent: January 5, 2021
    Assignee: PANASONIC INTELLECTURAL PROPERTY MANAGEMENT CO., LTD.
    Inventor: Emina Ikeuchi